logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. The Canadian hemophilia registry as the basis for a national system for monitoring the use of factor concentrates.

    Article - En anglais

    Background 

    Canada's publicly funded blood system has recently introduced high-purity concentrates as the standard treatment for individuals with hemophilia.

    The added cost and the need to document patient outcomes have prompted the consideration of a national blood product monitoring system.

    Study Design and Methods 

    This study investigates the suitability of the Canadian Hemophilia Registry (CHR) as the basis of such a monitoring system by assessing the degree to which it represents users of factor concentrates.

    Results 

    Currently, there are 1978 individuals registered with the CHR, of whom 1594 (81%) have hemophilia A and 384 (19%) have hemophilia B. The total prevalence is 7.2 per 105 population, with the prevalence of severe cases being 2.3 per 105.

    This overall prevalence is similar to that seen in other countries with national registries.

    The CHR national prevalence also compares favorably with that in the province of Quebec, where registration of users of blood products is compulsory.

    The CHR figures indicate that the number of persons currently infected with human immunodeficiency virus, both alive and dead, is 652, which is similar to the number of applicants (658) to the federal government's assistance program.

    Conclusion 

    The CHR includes the vast majority of factor concentrate users and is therefore ideal as the basis for a national monitoring system.

    Mots-clés Pascal : Facteur coagulation, Concentrat, Utilisation, Epidémiologie, Homme, Canada, Amérique du Nord, Amérique, Constituant sang, Transfusion

    Mots-clés Pascal anglais : Coagulation factor, Concentrate, Use, Epidemiology, Human, Canada, North America, America, Blood product, Transfusion

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 95-0439776

    Code Inist : 002B27D01. Création : 01/03/1996.